Answer
Ramucirumab binds VEGF receptor 2, blocking VEGF-A, VEGF-C and VEGF-D binding and thereby inhibiting receptor activation and downstream signalling, which neutralises ligand-induced proliferation and migration of human endothelial cells.
Sources for this answer
- Cyramza 10 mg/ml concentrate for solution for infusionEli Lilly and Company Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 18Document updated
Sources checked